Home›Trial›NCT06881784

🔬NCT06881784Phase 3RECRUITING

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Study Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Conditions

NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung Cancer NSCLC NSCLC (Non-small Cell Lung Carcinoma)NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions / Drugs

daraxonrasib docetaxel

View on ClinicalTrials.gov ↗

Sponsor

Revolution Medicines

Precision Oncology

Study Details

Enrollment420 participants

Primary Completion—

Lead SponsorRevolution Medicines, Inc.

Data Retrieved2026-04-11 04:26:28.070694+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.